223 related articles for article (PubMed ID: 17431765)
1. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
Leunen K; Drijkoningen M; Neven P; Christiaens MR; Van Ongeval C; Legius E; Amant F; Berteloot P; Vergote I
Breast Cancer Res Treat; 2008 Jan; 107(1):79-86. PubMed ID: 17431765
[TBL] [Abstract][Full Text] [Related]
2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
3. Numerous high-risk epithelial lesions in familial breast cancer.
Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
[TBL] [Abstract][Full Text] [Related]
4. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
5. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
6. Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.
Isern AE; Loman N; Malina J; Olsson H; Ringberg A
Eur J Surg Oncol; 2008 Oct; 34(10):1148-54. PubMed ID: 18434071
[TBL] [Abstract][Full Text] [Related]
7. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
8. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations.
Kauff ND; Brogi E; Scheuer L; Pathak DR; Borgen PI; Hudis CA; Offit K; Robson ME
Cancer; 2003 Apr; 97(7):1601-8. PubMed ID: 12655515
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
[TBL] [Abstract][Full Text] [Related]
10. Preoperative risk assessment among women undergoing bilateral prophylactic mastectomy for cancer risk reduction.
Rueth NM; McMahon M; Arrington AK; Swenson K; Leach J; Tuttle TM
Ann Surg Oncol; 2011 Sep; 18(9):2515-20. PubMed ID: 21424371
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic bilateral mastectomy: patterns of practice.
Metcalfe KA; Goel V; Lickley L; Semple J; Narod SA
Cancer; 2002 Jul; 95(2):236-42. PubMed ID: 12124821
[TBL] [Abstract][Full Text] [Related]
12. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
13. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
[TBL] [Abstract][Full Text] [Related]
14. Screening and follow-up of the patient at high risk for breast cancer.
Willey SC; Cocilovo C
Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
[TBL] [Abstract][Full Text] [Related]
15. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
[TBL] [Abstract][Full Text] [Related]
16. The development of interval breast malignancies in patients with BRCA mutations.
Komenaka IK; Ditkoff BA; Joseph KA; Russo D; Gorroochurn P; Ward M; Horowitz E; El-Tamer MB; Schnabel FR
Cancer; 2004 May; 100(10):2079-83. PubMed ID: 15139048
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
Reynolds C; Davidson JA; Lindor NM; Glazebrook KN; Jakub JW; Degnim AC; Sandhu NP; Walsh MF; Hartmann LC; Boughey JC
Ann Surg Oncol; 2011 Oct; 18(11):3102-9. PubMed ID: 21947588
[TBL] [Abstract][Full Text] [Related]
18. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
[TBL] [Abstract][Full Text] [Related]
19. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years.
Evans DG; Lalloo F; Hopwood P; Maurice A; Baildam A; Brain A; Barr L; Howell A
Eur J Surg Oncol; 2005 Dec; 31(10):1112-8. PubMed ID: 16005602
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment planning in newly diagnosed breast cancer patients at high risk for BRCA-1 or BRCA-2 mutation.
Chung MA; Cady B
Breast J; 2004; 10(6):473-4. PubMed ID: 15569200
[No Abstract] [Full Text] [Related]
[Next] [New Search]
